Dr Sung Pil Hong holds the esteemed position of CRUK Clinician Scientist Fellow within the Division of Cancer at the Department of Surgery and Cancer. He is an Honorary Consultant in Gastroenterology and a vital member of the early upper gastrointestinal cancer team at the Imperial College Healthcare NHS Trust.
His research is primarily centred on two critical areas: intratumoral heterogeneity and drug resistance, with a specific emphasis on oesophagogastric cancer.
At the heart of his research lies the exploration of intratumoral heterogeneity and its implications for treatment outcomes. Leveraging cutting-edge single-cell technologies, his lab meticulously tracks the dynamic changes in tumour heterogeneity during drug treatments, providing invaluable insights into cell type-specific drug response and cancer progression.
He is particularly intrigued by drug-tolerant persisters, a key contributor to drug resistance and early relapse. His research endeavours are dedicated to characterizing these persisters, shedding light on the mechanisms that drive resistance, and exploring novel strategies to combat this challenge.
In pursuing understanding persisters during drug treatment, His lab has made significant advancements in establishing patient-derived organoids as an ex-vivo model. This innovative approach enables the study of drug responses in a patient-specific context, opening new avenues for personalized treatment strategies.
et al., 2024, Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer., Clin Cancer Res
et al., 2020, Exploiting evolutionary steering to induce collateral drug sensitivity in cancer, Nature Communications, Vol:11, ISSN:2041-1723, Pages:1-14
et al., 2019, High-resolution label-free 3D mapping of extracellular pH of single living cells, Nature Communications, Vol:10, ISSN:2041-1723, Pages:1-9
et al., 2019, β-catenin activation down-regulates cell-cell junction-related genes and induces epithelial-to-mesenchymal transition in colorectal cancers, Scientific Reports, Vol:9, ISSN:2045-2322
et al., 2019, Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy, Nature Communications, Vol:10, ISSN:2041-1723